RCMI Coordinating Center (RCMI CC) Header Logo

Randal Wada, MD

TitleChief, Division of Hematology/Oncology
Faculty RankProfessor
InstitutionUniversity of Hawaii
AddressJohn A. Burns School of Medicine
University of Hawaii at Manoa
1319 PunahouĀ 
Honolulu HI 96826
vCardDownload vCard

    Collapse Research 
    Collapse research activities and funding
    R29NS032128     (WADA, RANDAL K)Jul 1, 1993 - Jun 30, 1998
    Role: Principal Investigator

    R01NS034432     (WADA, RANDAL K)Sep 1, 1995 - Nov 30, 2005
    Regulation of the N-myc oncogene in neuroblastoma
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Sholler GLS, Bergendahl G, Lewis EC, Kraveka J, Ferguson W, Nagulapally AB, Dykema K, Brown VI, Isakoff MS, Junewick J, Mitchell D, Rawwas J, Roberts W, Eslin D, Oesterheld J, Wada RK, Pastakia D, Harrod V, Ginn K, Saab R, Bielamowicz K, Glover J, Chang E, Hanna GK, Enriquez D, Izatt T, Halperin RF, Moore A, Byron SA, Hendricks WPD, Trent JM. Molecular-guided therapy for the treatment of patients with relapsed and refractory childhood cancers: a Beat Childhood Cancer Research Consortium trial. Genome Med. 2024 Feb 12; 16(1):28. PMID: 38347552.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    2. Oesterheld J, Ferguson W, Kraveka JM, Bergendahl G, Clinch T, Lorenzi E, Berry D, Wada RK, Isakoff MS, Eslin DE, Brown VI, Roberts W, Zage P, Harrod VL, Mitchell DS, Hanson D, Saulnier Sholler GL. Eflornithine as Postimmunotherapy Maintenance in High-Risk Neuroblastoma: Externally Controlled, Propensity Score-Matched Survival Outcome Comparisons. J Clin Oncol. 2024 Jan 01; 42(1):90-102. PMID: 37883734.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    3. Eslin D, Zage PE, Bergendahl G, Lewis E, Roberts W, Kraveka J, Mitchell D, Isakoff MS, Rawwas J, Wada RK, Fluchel M, Brown VI, Ginn K, Higgins T, BeeravallyNagulapally A, Dykema K, Hanna G, Ferguson W, Saulnier Sholler GL. A phase II trial of nifurtimox combined with topotecan and cyclophosphamide for refractory or relapsed neuroblastoma and medulloblastoma. Int J Cancer. 2023 Sep 01; 153(5):1026-1034. PMID: 37246577.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    4. Kraveka JM, Lewis EC, Bergendahl G, Ferguson W, Oesterheld J, Kim E, Nagulapally AB, Dykema KJ, Brown VI, Roberts WD, Mitchell D, Eslin D, Hanson D, Isakoff MS, Wada RK, Harrod VL, Rawwas J, Hanna G, Hendricks WPD, Byron SA, Snuderl M, Serrano J, Trent JM, Saulnier Sholler GL. A pilot study of genomic-guided induction therapy followed by immunotherapy with difluoromethylornithine maintenance for high-risk neuroblastoma. Cancer Rep (Hoboken). 2022 Nov; 5(11):e1616. PMID: 35355452.
      Citations: 4     Fields:    Translation:Humans
    5. Byron SA, Hendricks WPD, Nagulapally AB, Kraveka JM, Ferguson WS, Brown VI, Eslin DE, Mitchell D, Cornelius A, Roberts W, Isakoff MS, Oesterheld JE, Wada RK, Rawwas J, Neville K, Zage PE, Harrod VL, Bergendahl G, VanSickle E, Dykema K, Bond J, Chou HC, Wei JS, Wen X, Reardon HV, Roos A, Nasser S, Izatt T, Enriquez D, Hegde AM, Cisneros F, Christofferson A, Turner B, Szelinger S, Keats JJ, Halperin RF, Khan J, Saulnier Sholler GL, Trent JM. Genomic and Transcriptomic Analysis of Relapsed and Refractory Childhood Solid Tumors Reveals a Diverse Molecular Landscape and Mechanisms of Immune Evasion. Cancer Res. 2021 12 01; 81(23):5818-5832. PMID: 34610968.
      Citations: 7     Fields:    Translation:HumansCells
    6. Abe K, Dowsett L, Wada R, Hutchins K. A pediatric case of acute myeloid leukemia with KMT2A gene rearrangement t(10;11) and 16p11.2 microdeletion syndrome. Pediatr Blood Cancer. 2021 02; 68(2):e28764. PMID: 33058483.
      Citations:    Fields:    Translation:HumansCells
    7. Wada RK. Leadership, behavioral science, and interprofessional teamwork. Transl Behav Med. 2020 10 08; 10(4):905-908. PMID: 33030530.
      Citations:    Fields:    Translation:Humans
    8. Lewis EC, Kraveka JM, Ferguson W, Eslin D, Brown VI, Bergendahl G, Roberts W, Wada RK, Oesterheld J, Mitchell D, Foley J, Zage P, Rawwas J, Rich M, Lorenzi E, Broglio K, Berry D, Saulnier Sholler GL. A subset analysis of a phase II trial evaluating the use of DFMO as maintenance therapy for high-risk neuroblastoma. Int J Cancer. 2020 12 01; 147(11):3152-3159. PMID: 32391579.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    9. Wada RK, Wong L, Flohr A, Kurahara D, Arndt R, Deutsch MJ, Ing D, Richardson K, Munro A, Kaneshige L, Mullis M, Hatae M, Albright CL. Engaging a Community Chaplaincy Resource for Interprofessional Health Care Provider Training in Facilitating Family Decision Making for Children at End-of-Life. Hawaii J Med Public Health. 2019 06; 78(6 Suppl 1):37-40. PMID: 31285967.
      Citations:    Fields:    Translation:Humans
    10. Sholler GLS, Ferguson W, Bergendahl G, Bond JP, Neville K, Eslin D, Brown V, Roberts W, Wada RK, Oesterheld J, Mitchell D, Foley J, Parikh NS, Eshun F, Zage P, Rawwas J, Sencer S, Pankiewicz D, Quinn M, Rich M, Junewick J, Kraveka JM. Maintenance DFMO Increases Survival in High Risk Neuroblastoma. Sci Rep. 2018 09 27; 8(1):14445. PMID: 30262852.
      Citations: 41     Fields:    Translation:HumansCTClinical Trials
    11. Saulnier Sholler GL, Gerner EW, Bergendahl G, MacArthur RB, VanderWerff A, Ashikaga T, Bond JP, Ferguson W, Roberts W, Wada RK, Eslin D, Kraveka JM, Kaplan J, Mitchell D, Parikh NS, Neville K, Sender L, Higgins T, Kawakita M, Hiramatsu K, Moriya SS, Bachmann AS. A Phase I Trial of DFMO Targeting Polyamine Addiction in Patients with Relapsed/Refractory Neuroblastoma. PLoS One. 2015; 10(5):e0127246. PMID: 26018967.
      Citations: 61     Fields:    Translation:HumansCTClinical Trials
    12. Wada RK, Glaser DW, Bantum EO, Orimoto T, Steffen AD, Elia JL, Albright CL. Hawai'i's multiethnic adolescent and young adult survivors of childhood cancer: are their health behavior risks similar to state and national samples? Hawaii J Med Public Health. 2013 Nov; 72(11):380-5. PMID: 24251083.
      Citations: 8     Fields:    Translation:Humans
    13. Gawecka JE, Geerts D, Koster J, Caliva MJ, Sulzmaier FJ, Opoku-Ansah J, Wada RK, Bachmann AS, Ramos JW. PEA15 impairs cell migration and correlates with clinical features predicting good prognosis in neuroblastoma. Int J Cancer. 2012 Oct 01; 131(7):1556-68. PMID: 22213050.
      Citations: 10     Fields:    Translation:HumansAnimalsCells
    14. Kanemaru KK, Tuthill MC, Takeuchi KK, Sidell N, Wada RK. Retinoic acid induced downregulation of MYCN is not mediated through changes in Sp1/Sp3. Pediatr Blood Cancer. 2008 Apr; 50(4):806-11. PMID: 17554788.
      Citations: 5     Fields:    Translation:HumansCells
    15. Kollman C, Abella E, Baitty RL, Beatty PG, Chakraborty R, Christiansen CL, Hartzman RJ, Hurley CK, Milford E, Nyman JA, Smith TJ, Switzer GE, Wada RK, Setterholm M. Assessment of optimal size and composition of the U.S. National Registry of hematopoietic stem cell donors. Transplantation. 2004 Jul 15; 78(1):89-95. PMID: 15257044.
      Citations: 36     Fields:    Translation:Humans
    16. Iwamoto LM, Fujiwara N, Nakamura KT, Wada RK. Na-K-2Cl cotransporter inhibition impairs human lung cellular proliferation. Am J Physiol Lung Cell Mol Physiol. 2004 Sep; 287(3):L510-4. PMID: 15155267.
      Citations: 14     Fields:    Translation:HumansCells
    17. Wada RK, Bradford A, Moogk M, Yim R, Strong DM, Drachman J, Reems JA. Cord blood units collected at a remote site: a collaborative endeavor to collect umbilical cord blood through the Hawaii Cord Blood Bank and store the units at the Puget Sound Blood Center. Transfusion. 2004 Jan; 44(1):111-8. PMID: 14692976.
      Citations: 1     Fields:    Translation:HumansCells
    18. Tuthill MC, Wada RK. Targeting oncogene expression in a childhood cancer. Hawaii Med J. 2003 Oct; 62(10):224-5. PMID: 14631595.
      Citations:    Fields:    Translation:HumansCells
    19. Tuthill MC, Wada RK, Arimoto JM, Sugino CN, Kanemaru KK, Takeuchi KK, Sidell N. N-myc oncogene expression in neuroblastoma is driven by Sp1 and Sp3. Mol Genet Metab. 2003 Sep-Oct; 80(1-2):272-80. PMID: 14567977.
      Citations: 5     Fields:    Translation:HumansAnimalsCells
    20. Iwamoto LM, Nakamura KT, Wada RK. Immunolocalization of a Na-K-2Cl cotransporter in human tracheobronchial smooth muscle. J Appl Physiol (1985). 2003 Apr; 94(4):1596-601. PMID: 12471046.
      Citations: 4     Fields:    Translation:HumansCells
    Wada's Networks
    Click the
    buttons for more information and interactive visualizations!
    Concepts (149)
    Co-Authors (4)
    Similar People (60)
    Same Department Expand Description
    RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

    For technical support please contact support